A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis (Q33379045)

26 July 2017

title

A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis (English)

1 reference

26 July 2017

0 references

1 reference

ChEBI release 2020-05-28

Nicolas Veziris

1

0 references

author name string

Murad Ibrahim

2

1 reference

26 July 2017

Nacer Lounis

3

1 reference

26 July 2017

Aurelie Chauffour

4

1 reference

26 July 2017

Chantal Truffot-Pernot

5

1 reference

26 July 2017

Koen Andries

6

1 reference

26 July 2017

Vincent Jarlier

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

23 October 2008

1 reference

American Journal of Respiratory and Critical Care Medicine

26 July 2017

published in

1 reference

26 July 2017

volume

179

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

75-79

1 reference

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200711-1736OC

10.1164/RCCM.200711-1736OC

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference